初免-加强疫苗接种后肺CD4+ T细胞的扩增与留存与抗土拉热免疫的持久性和强度改善相关
研究以土拉弗朗西斯菌强毒株SchuS4(Ftt)为对象,探讨初免-加强策略扩增高亲和力CD4+ T细胞能否提升疫苗对Ftt攻击的保护。结果显示该策略增加了高亲和力CD4+ T细胞池,与更高攻击剂量及接种后期攻击后生存改善相关,表位选择和扩增抗原特异性T细胞的接种策略均与更优免疫相关。
要点
- 初免-加强策略扩增高亲和力CD4+ T细胞池。
- 该扩增与更高剂量强毒Ftt攻击后生存改善相关。
- 该扩增亦与接种后期攻击后生存改善相关。
核心结论
- 表位选择与扩增抗原特异性T细胞的接种策略均与以生存衡量的更优抗Ftt免疫相关。
研究设计与样本
- 原文为针对土拉弗朗西斯菌强毒株SchuS4(Ftt)的初免-加强疫苗接种研究。
主要发现
- 初免-加强策略增加了高亲和力CD4+ T细胞池。
- 高亲和力CD4+ T细胞池扩大与更高剂量强毒Ftt攻击后生存改善相关。
- 高亲和力CD4+ T细胞池扩大与接种后期攻击后生存改善相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Francisella tularensis subsp. tularensis strain SchuS4 (Ftt) is a highly virulent intracellular bacterium. Inhalation of 10 or fewer organisms results in an acute and potentially lethal disease called pneumonic tularemia. Ftt infections occur naturally in the U.S. and Ftt was developed as a bioweapon. Thus, there is a need for vaccines that protect against this deadly pathogen. Although a live vaccine strain of Francisella tularensis (LVS) exists, LVS fails to generate long-lived protective immunity against modest challenge doses of Ftt. We recently identified an important role for high avidity CD4+ T cells in short-term protection and hypothesized that expanding this pool of cells would improve overall vaccine efficacy with regard to longevity and challenge dose. In support of our hypothesis, application of a prime/boost vaccination strategy increased the pool of high avidity CD4+ T cells which correlated with improved survival following challenge with either increased doses of virulent Ftt or at late time points after vaccination. In summary, we demonstrate that both epitope selection and vaccination strategies that expand antigen-specific T cells correlate with superior immunity to Ftt as measured by survival.
引用
- Roberts LM, Wehrly TD, Crane DD, et al. Expansion and retention of pulmonary CD4+ T cells after prime boost vaccination correlates with improved longevity and strength of immunity against tularemia. Vaccine. 2017. PMID: 28372827. doi:10.1016/j.vaccine.2017.03.064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。